J
John Norrie
Researcher at University of Edinburgh
Publications - 383
Citations - 23367
John Norrie is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 60, co-authored 330 publications receiving 20698 citations. Previous affiliations of John Norrie include Western General Hospital & University of Aberdeen.
Papers
More filters
Journal ArticleDOI
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
James Shepherd,Gerard J. Blauw,Michael B. Murphy,Edward L.E.M. Bollen,Brendan M. Buckley,Stuart M. Cobbe,Ian Ford,Allan Gaw,Michael E. Hyland,J. Wouter Jukema,Adriaan M. Kamper,Peter W. Macfarlane,A. Edo Meinders,John Norrie,Chris J. Packard,Ivan J. Perry,David J. Stott,Brian Sweeney,Gillian Twomey,Rudi G. J. Westendorp +19 more
TL;DR: Pravastatin given for 3 years reduced the risk of coronary disease in elderly individuals and was extended to elderly individuals the treatment strategy currently used in middle aged people.
Journal ArticleDOI
West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials
J. Shepherd,Stuart M. Cobbe,AR Lorimer,James H. McKillop,Jane B. Ford,Christopher J. Packard,Peter W. Macfarlane,Chris Isles,MF Oliver,A. F. Lever,BW Brown,Jgg Ledingham,SJ Pocock,BM Rifkind,B. D. Vallance,David Ballantyne,L Anderson,D Duncan,Sharon Kean,A Lawrence,John J. McGrath,K Montgomery,John Norrie,M Percy,E Pomphrey,Andrew J. O. Whitehouse,Peter Cameron,P Parker,F Porteous,L Fletcher,C Kilday,D Shoat,S Latif,James L. Kennedy,M A Bell,R Birrell,M Mellies,J Meyer,W Campbell +38 more
Journal ArticleDOI
Pravastatin and the Development of Diabetes Mellitus Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study
Dilys J. Freeman,John Norrie,Naveed Sattar,R. Dermot G. Neely,Stuart M. Cobbe,Ian Ford,Christopher G. Isles,A.Ross Lorimer,Peter W. Macfarlane,James H. McKillop,Christopher J. Packard,James Shepherd,Allan Gaw +12 more
TL;DR: By lowering plasma triglyceride levels, pravastatin therapy may favorably influence the development of diabetes, but other explanations, such as the anti-inflammatory properties of this drug in combination with its endothelial effects, cannot be excluded with these analyses.
Journal Article
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
Chris J. Packard,J. Shepherd,Stuart M. Cobbe,Jane B. Ford,Chris Isles,James H. McKillop,Peter W. Macfarlane,AR Lorimer,John Norrie,W Scotland Coronary Prevention Study Grp +9 more
TL;DR: There is no CHD risk reduction unless LDL levels are reduced, but a fall in the range of 24% is sufficient to produce the full benefit in patients taking this dose of pravastatin, which is proportionally the same regardless of baseline lipid phenotype.
Journal ArticleDOI
Patterns of treatment response in newly diagnosed epilepsy
TL;DR: Most patients with newly diagnosed epilepsy had a constant course which could usually be predicted early and the chance of seizure freedom declined with successive drug regimens, most markedly from the first to the third and among patients with localization-related epilepsies.